Cargando…
Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias
Elagolix is an FDA-approved treatment for moderate-to-severe pain associated with endometriosis but has been associated with increased acute porphyric attacks in women with the acute hepatic porphyrias (AHPs). A fluorescence-based screening assay for drug porphyrogenicity in LMH cells indicates that...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465260/ https://www.ncbi.nlm.nih.gov/pubmed/36105850 http://dx.doi.org/10.1016/j.ymgmr.2022.100915 |